Vestal Point Capital, LP Verve Therapeutics, Inc. Call Options Transaction History
Vestal Point Capital, LP
- $1.34 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VERV
# of Institutions
176Shares Held
71.8MCall Options Held
115KPut Options Held
144K-
Alphabet Inc. Mountain View, CA12.3MShares$74.7 Million3.79% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$40.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$31.8 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.53MShares$27.4 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.87MShares$23.4 Million0.01% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $363M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...